help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, M. D.
Right arrow Articles by Moses, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, M. D.
Right arrow Articles by Moses, H. L.

American Journal of Pathology, Vol 141, 633-642, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Transforming growth factor-beta and transforming growth factor beta- receptor expression in human meningioma cells

MD Johnson, CF Federspiel, LI Gold and HL Moses
Division of Neuropathology, Vanderbilt University Medical School, Nashville, Tennessee 37232.

The transforming growth factor-beta (TGF beta) family in mammals includes three closely related peptides that influence proliferation and numerous physiologic processes in most mesenchymal cells. In this study, Northern blots, immunohistochemistry, TGF beta radioreceptor assays, TGF beta receptor affinity labeling and [3H] thymidine incorporation were used to evaluate whether primary cell cultures of human meningiomas synthesize the three TGF beta isoforms, bear TGF beta receptors, and respond to TGF beta. Transcripts for TGF beta 1 and 2 were detected in the three cases analyzed. Transforming growth factor- beta 1 immunoreactivity was detected in three of six cases, and TGF beta 2 and 3 immunoreactivity were detected in each case analyzed. Media conditioned by cells cultured from six meningiomas also contained latent TGF beta-like activity. Transforming growth factor-beta receptor cross-linking studies identified TGF beta binding sites corresponding to the type 1, type 2, and type 3 receptors on meningioma cells. Treatment with active TGF beta 1 produced a statistically significant reduction in [3H] thymidine incorporation after stimulation with 10% fetal calf serum and epidermal growth factor in all six cases studied.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Sadetzki, P. Flint-Richter, S. Starinsky, I. Novikov, Y. Lerman, B. Goldman, and E. Friedman
Genotyping of Patients with Sporadic and Radiation-Associated Meningiomas
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 969 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. Laitakari and F. Stenback
Collagen Matrix in Development and Progression of Experimentally Induced Respiratory Neoplasms in the Hamster
Toxicol Pathol, August 1, 2001; 29(5): 514 - 527.
[Abstract] [PDF]

Home page
 Genes Dev.Home page
D F Pierce, M D Johnson, Y Matsui, S D Robinson, L I Gold, A F Purchio, C W Daniel, B L Hogan, and H L Moses
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1.
Genes & Dev., December 1, 1993; 7(12a): 2308 - 2317.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Society for Investigative Pathology.